In spring 2026, three things happened in close succession. CNN published "Peptides: what's real, what's risky and what's next." Eric Topol published "The Peptide Craze" on Ground Truths. And a stretched wellness industry kept doing exactly what those pieces were warning about — prescribing without baseline labs, sourcing without 503A oversight, titrating without follow-up, and selling without disclosing what the evidence supports.
The critics are largely correct. The market is full of practices that deserve the skepticism — some NP-led, some physician-led, some neither. The shorthand "physician vs. NP" is too coarse: there are excellent NP-staffed practices and there are physician-owned practices that are doing exactly what the critics describe. What matters is not the title on the door. It is what the practice operationalizes — structured labs, vetted compounding, defined endpoints, evidence tiers in writing, and an honest informed-consent process the patient can audit.
This page is the side-by-side. Each concern the skeptics raise — fairly — paired with exactly what Limitless does about it. No vague reassurance; the specific operational answer. If a competing clinic does the same things, that is good for patients. The differentiation is the operational rigor, in writing.
The CNN piece flags it directly: research-grade powder, gray-market imports, peptides "for research only" being injected into humans. The patient often has no way to find out.
Every Limitless peptide and compounded hormone is dispensed through a licensed 503A pharmacy. We audit our partners on USP 797/795 compliance, COA reporting, and beyond-use dating. We are on track for two qualified pharmacy partners on file by June 1, 2026 — operational redundancy so a single supply event cannot interrupt your care. Pharmacy name and COA available on request.
Topol's central frustration: TRT and peptides being initiated with no objective starting point, no follow-up labs, no way to know whether the intervention is working or whether the patient is drifting into harm (elevated hematocrit, lipid shifts, hepatic stress).
Every Limitless patient gets a comprehensive baseline lab panel before a prescription is written — total and free testosterone, estradiol, SHBG, LH, FSH, prolactin, complete metabolic panel, complete blood count, lipid panel, hsCRP, fasting insulin, A1c, IGF-1, ferritin, thyroid, vitamin D. We review the results with the patient before prescribing. Labs at 90 days. Labs again at 6 months and annually. No exceptions.
"Feel-better peptides" without a named clinical indication. Open-ended protocols that just keep going. No clearly defined endpoint where success or failure can be measured.
Every Limitless prescription is tied to a named clinical indication in the chart: hypogonadism by Endocrine Society criteria, perimenopausal symptom burden, tendinopathy with stalled rehab, visceral adiposity for tesamorelin, etc. BPC-157 and TB-500 courses are defined as 4–8 week protocols with documented reassessment — not open-ended scripts. If the indication isn't there, the prescription isn't either.
"Reverses aging." "Cures fatigue." "Adds a decade." The marketing oversteps what the trials show. Patients are misled about the magnitude and certainty of effect.
Our peptide evidence framework sorts every molecule on our menu into FDA-approved, supported-with-meta-analysis, or supported-by-mechanism-and-pilots. The patient sees the tier in plain language before signing consent. Tesamorelin and daily tadalafil are FDA-approved. BPC-157 is voluminous preclinical with thin human data. NAD+ is well-characterized biology with maturing endpoint trials. We say so out loud.
In many regenerative-medicine practices the patient meets one clinician for the consult, a different one signs the prescription, and a third manages follow-up. Scope-of-practice questions get answered by org charts rather than by who actually understands the patient's labs over time.
Every Limitless protocol is written by Joshua Hare, DO — an osteopathic physician with a hospital-based, interventional clinical background, currently practicing at Interventional Pain Consultants in Dalton. There is no "supervising physician" relationship behind a curtain and no rotating prescriber. The physician you book with is the physician who reads your labs, signs your protocol, and reviews your follow-up. Single point of clinical responsibility from intake through annual maintenance.
Initiation without surveillance. No one checking hematocrit on TRT at 90 days. No one re-running estradiol after a dose change. No one watching the prostate or the lipid panel. Drift becomes harm.
The Limitless lab cadence is 0 → 90 days → 6 months → annual, with interim labs after any dose change. Hematocrit, estradiol, SHBG, lipids, LFTs, PSA (men 40+), thyroid, A1c. We titrate — we do not "set and forget." When a value moves, we have a chart-documented response: dose adjustment, donation referral for elevated hematocrit, hepatology workup for persistent transaminitis, etc.
The peptide market is increasingly cluttered with products whose pharmacokinetic or safety data does not support common use. The default menu of many practices is shaped by what is profitable, not what is supportable.
PT-141 is not on our default menu — selected use only with documented indication. Oral BPC-157 is not on our menu — the route is not well-characterized. NAD+ patches and nasal sprays are not on our menu — the pharmacokinetic data does not support them. We publish what we don't prescribe and why, on this page and inside our research library.
The April 23, 2026 reclassification restored compounded peptides, but the July 23–24 PCAC meeting may reshape the durable shelf status. Patients deserve to know that the legal picture in October 2026 may differ from the picture today.
See our legal-status briefing and the BPC-157 PCAC summary. Two qualified 503A partners by June 1 (insulation against single-source supply tightening). A planned post-PCAC update by July 30 with operational implications for current patients. Indication-anchored prescribing means we are not exposed to "discontinued wellness peptide" risk.
Joshua Hare, DO — the physician you book with — is the physician who reads your labs and signs your protocol. No supervising-physician proxies.
Licensed compounding pharmacy on every prescription. COA available on request. Two-partner redundancy targeted by June 1, 2026.
Comprehensive baseline. Labs at 90 days, 6 months, and annually. Interim labs after any dose change. No prescriptions without labs.
Every prescription tied to a named clinical indication. Defined courses for peptides. Documented reassessment.
You see the literature behind the prescription — FDA-approved, meta-analysis, or mechanism-and-pilot — in writing, before you sign.
If the indication isn't there, or the evidence doesn't support it, we say so. We publish what we don't prescribe.
Every Limitless protocol has a paper trail. Our research library is public, primary-source-cited, and physician-authored. If you are skeptical, start there.
Open the Research LibraryWhen you are ready, book a consult — we will go through your goals, your history, and exactly what an indicated, lab-anchored Limitless protocol would look like for you.